

Dirk Reinhardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/622273/publications.pdf>

Version: 2024-02-01

178
papers

11,221
citations

20817

60
h-index

34986

98
g-index

189
all docs

189
docs citations

189
times ranked

11381
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29341.	1.5	5
2	The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. <i>Blood</i> , 2022, 139, 651-665.	1.4	20
3	Pediatric Acute Myeloid Leukemia—Past, Present, and Future. <i>Journal of Clinical Medicine</i> , 2022, 11, 504.	2.4	27
4	Optical Genome Mapping as a Diagnostic Tool in Pediatric Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 2058.	3.7	16
5	Efficient Small Extracellular Vesicles (EV) Isolation Method and Evaluation of EV-Associated DNA Role in Cell–Cell Communication in Cancer. <i>Cancers</i> , 2022, 14, 2068.	3.7	6
6	Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. <i>Biomedicines</i> , 2022, 10, 1530.	3.2	1
7	The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 630-634.	3.5	29
8	Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. <i>Cancers</i> , 2021, 13, 789.	3.7	10
9	Redirecting the Immune Microenvironment in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1423.	3.7	23
10	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. <i>Cancers</i> , 2021, 13, 1876.	3.7	7
11	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	3.7	30
12	Far from Health: The Bone Marrow Microenvironment in AML, A Leukemia Supportive Shelter. <i>Children</i> , 2021, 8, 371.	1.5	4
13	BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone. <i>Cancer Genetics</i> , 2021, 254-255, 70-74.	0.4	3
14	A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1025-1037.	4.7	4
15	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	9.4	110
16	Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS). <i>Klinische Padiatrie</i> , 2021, 233, 267-277.	0.6	4
17	A homozygous nonsense mutation early in exon 5 of BRCA2 is associated with very severe Fanconi anemia. <i>European Journal of Medical Genetics</i> , 2021, 64, 104260.	1.3	5
18	Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 4817.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO Clinical Cancer Informatics, 2021, 5, 1034-1043.	2.1	18
20	Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial. Leukemia, 2020, 34, 613-624.	7.2	19
21	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia, 2020, 34, 151-166.	7.2	53
22	Veno-Venous Extracorporeal Membrane Oxygenation in Adult Patients with Sickle Cell Disease and Acute Chest Syndrome: a Single-Center Experience. Hemoglobin, 2020, 44, 71-77.	0.8	4
23	Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. British Journal of Haematology, 2020, 190, 198-208.	2.5	19
24	Exposure of Patient-Derived Mesenchymal Stromal Cells to TGFB1 Supports Fibrosis Induction in a Pediatric Acute Megakaryoblastic Leukemia Model. Molecular Cancer Research, 2020, 18, 1603-1612.	3.4	1
25	Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective Iâ€œBFM analysis of 333 children. British Journal of Haematology, 2020, 189, 745-750.	2.5	12
26	Insights into the limitations of transient expression systems for the functional study of p53 acetylation site and oncogenic mutants. Biochemical and Biophysical Research Communications, 2020, 524, 990-995.	2.1	2
27	Phosphoâ€œProfiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia. HemaSphere, 2020, 4, e312.	2.7	7
28	Early deaths from childhood cancer in Germany 1980-2016. Cancer Epidemiology, 2020, 65, 101669.	1.9	5
29	Evaluation of dsDNA from extracellular vesicles (EVs) in pediatric AML diagnostics. Annals of Hematology, 2020, 99, 459-475.	1.8	25
30	Social inequalities in the participation and activity of children and adolescents with leukemia, brain tumors, and sarcomas (SUPATEEN): a protocol for a multicenter longitudinal prospective observational study. BMC Pediatrics, 2020, 20, 48.	1.7	3
31	Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-MÃ¼nster study group. Haematologica, 2019, 104, 120-127.	3.5	38
32	Phase I doseâ€œescalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatric Blood and Cancer, 2019, 66, e27900.	1.5	6
33	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell, 2019, 36, 123-138.e10.	16.8	93
34	Mutated <i>WT1</i> , <i>FLT3-ITD</i> , and <i>NUP98-NSD1</i> Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia. Journal of Oncology, 2019, 2019, 1-15.	1.3	48
35	Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicleâ€œderived RNA. Annals of Hematology, 2019, 98, 595-603.	1.8	18
36	Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology, 2019, 186, e7-e11.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. <i>Leukemia</i> , 2018, 32, 2167-2177.	7.2	155
38	An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 523-527.	2.5	12
39	Panton-Valentine Leukocidin associated with <i>S. aureus</i> osteomyelitis activates platelets via neutrophil secretion products. <i>Scientific Reports</i> , 2018, 8, 2185.	3.3	27
40	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. <i>Blood</i> , 2018, 132, 264-276.	1.4	70
41	Single-cell whole exome and targeted sequencing in NPM1/FLT3 positive pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26848.	1.5	12
42	Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1007-1016.	1.6	67
43	Cardio-toxicity in childhood cancer survivors – Cure is not enough. <i>Journal of Thoracic Disease</i> , 2018, 10, S4344-S4350.	1.4	6
44	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. <i>Blood</i> , 2018, 132, 1584-1592.	1.4	45
45	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	27.8	236
46	Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL. <i>Blood Advances</i> , 2018, 2, 1382-1385.	5.2	59
47	Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. <i>Blood Advances</i> , 2018, 2, 1532-1540.	5.2	36
48	Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. <i>Haematologica</i> , 2018, 103, 1484-1492.	3.5	24
49	Two cancer-predisposing variants in one family: Incidental finding of a fumarate hydrogenase (<i>FH</i>) germline variant in a family with Fraumeni syndrome. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27254.	1.5	0
50	First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26461.	1.5	32
51	Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. <i>Nature Genetics</i> , 2017, 49, 451-456.	21.4	152
52	Childhood cancer predisposition syndromes – A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	1.2	200
53	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. <i>Blood</i> , 2017, 129, 3314-3321.	1.4	64
54	Clinical Use of Clofarabine for Adults and Children with Leukemia. , 2017, , 287-309.		1

#	ARTICLE	IF	CITATIONS
55	A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl. <i>Leukemia and Lymphoma</i> , 2017, 58, 718-721.	1.3	3
56	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26664.	1.5	14
57	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 1449-1456.	1.8	32
58	The non-coding RNA landscape of human hematopoiesis and leukemia. <i>Nature Communications</i> , 2017, 8, 218.	12.8	131
59	A specific dietary intervention to restore brain structure and function after ischemic stroke. <i>Theranostics</i> , 2017, 7, 493-512.	10.0	48
60	Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1070-1074.	1.5	19
61	Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1677-1679.	1.5	18
62	Coexpression of Multiple ABC Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 242-247.	1.5	35
63	Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis. <i>Pediatric Blood and Cancer</i> , 2016, 63, 640-645.	1.5	28
64	Identification of a Cryptic Insertion ins(11;X)(q23;q28q12) Resulting in a KMT2A/FLNA Fusion in a 13-Month-Old Child with Acute Myelomonocytic Leukemia. <i>Cytogenetic and Genome Research</i> , 2016, 150, 281-286.	1.1	2
65	Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. <i>Blood</i> , 2016, 127, 3424-3430.	1.4	79
66	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	2.8	262
67	Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. <i>Cancer</i> , 2016, 122, 3821-3830.	4.1	92
68	Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2776-2783.	1.6	48
69	PHF6 mutations in paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 967-971.	2.5	18
70	MicroRNA-106b-25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 48412-48422.	1.8	20
71	BCOR and BCORL1 mutations in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e194-e195.	3.5	19
72	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015, 126, 1575-1584.	1.4	69

#	ARTICLE	IF	CITATIONS
73	Subtype prediction in pediatric acute myeloid leukemia: classification using differential network rank conservation revisited. <i>BMC Bioinformatics</i> , 2015, 16, 305.	2.6	2
74	Family History and Relapse in Pediatric Acute Myeloid Leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2235-2237.	1.5	2
75	Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. <i>Annals of Hematology</i> , 2015, 94, 1327-1336.	1.8	54
76	Clinical Impact of Additional Cytogenetic Aberrations, <i>ckIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 4247-4258.	1.6	75
77	Recurrent deletions of <i>IKZF1</i> in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1151-1159.	3.5	37
78	Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific <i>MLL</i> - <i>FNBP1</i> fusion gene. <i>Leukemia and Lymphoma</i> , 2015, 56, 793-796.	1.3	4
79	Somatic thrombopoietin (THPO) gene mutations in childhood myeloid leukemias. <i>International Journal of Hematology</i> , 2015, 102, 140-143.	1.6	4
80	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	1.6	277
81	Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 1353-1359.	7.0	48
82	Gene Expression Profiles Associated with Pediatric Relapsed AML. <i>PLoS ONE</i> , 2015, 10, e0121730.	2.5	22
83	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. <i>Haematologica</i> , 2014, 99, 1472-1478.	3.5	42
84	Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. <i>British Journal of Haematology</i> , 2014, 166, 902-910.	2.5	22
85	LincRNAs <i>MONC</i> and <i>MIR100HG</i> act as oncogenes in acute megakaryoblastic leukemia. <i>Molecular Cancer</i> , 2014, 13, 171.	19.2	131
86	<i>miR-99a/100</i> tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between <i>TGFβ2</i> and Wnt signaling. <i>Genes and Development</i> , 2014, 28, 858-874.	5.9	136
87	Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e130-e132.	3.5	11
88	Cooperativity of <i>RUNX1</i> and <i>CSF3R</i> mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. <i>Blood</i> , 2014, 123, 2229-2237.	1.4	135
89	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. <i>Haematologica</i> , 2014, 99, 299-307.	3.5	34
90	Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. <i>Blood</i> , 2013, 122, 37-43.	1.4	151

#	ARTICLE	IF	CITATIONS
91	Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium. <i>Journal of Clinical Oncology</i> , 2013, 31, 2460-2468.	1.6	75
92	Absence of <i>SBDS</i> mutations in sporadic paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 559-561.	2.5	3
93	Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells. <i>International Journal of Cancer</i> , 2013, 132, 766-774.	5.1	40
94	Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 599-607.	1.6	197
95	<i>NADH</i> dehydrogenase subunit 4 variant sequences in childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 161, 891-895.	2.5	3
96	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group. <i>Blood</i> , 2013, 122, 2704-2713.	1.4	86
97	Engagement of SIRP \pm Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia Cells. <i>PLoS ONE</i> , 2013, 8, e52143.	2.5	15
98	Prospects and Challenges of Reprogrammed Cells in Hematology and Oncology. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 507-528.	0.8	7
99	High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. <i>Blood</i> , 2012, 120, 2064-2075.	1.4	62
100	Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. <i>Journal of Experimental Medicine</i> , 2012, 209, 2017-2031.	8.5	87
101	The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. <i>Haematologica</i> , 2012, 97, 551-559.	3.5	87
102	High frequency of copy number alterations in myeloid leukaemia of Down syndrome. <i>British Journal of Haematology</i> , 2012, 158, 800-803.	2.5	10
103	The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. <i>Haematologica</i> , 2012, 97, 21-29.	3.5	78
104	Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 424, 371-377.	2.1	27
105	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012, 120, 3187-3205.	1.4	451
106	Paediatric palliative home care in areas of Germany with low population density and long distances: a questionnaire survey with general paediatricians. <i>BMC Research Notes</i> , 2012, 5, 498.	1.4	9
107	<i>CBL</i> mutations do not frequently occur in paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 577-584.	2.5	7
108	miRNAs can increase the efficiency of ex vivo platelet generation. <i>Annals of Hematology</i> , 2012, 91, 1673-1684.	1.8	34

#	ARTICLE	IF	CITATIONS
109	Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2012, 58, 715-721.	1.5	44
110	Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 689-695.	2.8	114
111	A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL. <i>British Journal of Haematology</i> , 2012, 157, 180-187.	2.5	9
112	Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). <i>Annals of Hematology</i> , 2012, 91, 9-18.	1.8	73
113	Oxaliplatin, Irinotecan, and Gemcitabine. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 344-349.	0.6	12
114	Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. <i>Blood</i> , 2011, 118, 2222-2238.	1.4	92
115	High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). <i>Blood</i> , 2011, 117, 928-935.	1.4	17
116	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. <i>Blood</i> , 2011, 117, 7102-7111.	1.4	58
117	NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. <i>Blood</i> , 2011, 118, 3645-3656.	1.4	250
118	Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). <i>Blood</i> , 2011, 118, 5409-5415.	1.4	56
119	Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 221-230.	3.5	98
120	DNMT3A mutations are rare in childhood acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1238-1240.	3.5	34
121	CNS irradiation in pediatric acute myeloid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. <i>Pediatric Blood and Cancer</i> , 2011, 57, 986-992.	1.5	25
122	Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1478-1487.	3.5	102
123	Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 384-392.	3.5	74
124	Long term survival in children with acute leukaemia and complications requiring mechanical ventilation. <i>Archives of Disease in Childhood</i> , 2011, 96, 1026-1032.	1.9	8
125	High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. <i>Blood</i> , 2010, 116, 2752-2758.	1.4	71
126	FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. <i>Leukemia Research</i> , 2010, 34, 1302-1307.	0.8	7

#	ARTICLE	IF	CITATIONS
127	Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. <i>British Journal of Haematology</i> , 2010, 148, 768-776.	2.5	75
128	Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. <i>British Journal of Haematology</i> , 2010, 149, 84-92.	2.5	92
129	Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. <i>British Journal of Haematology</i> , 2010, 149, 399-409.	2.5	52
130	Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2010, 28, 2682-2689.	1.6	190
131	Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. <i>Genes and Development</i> , 2010, 24, 1659-1672.	5.9	122
132	No Prognostic Impact of the <i>WT1</i> Gene Single Nucleotide Polymorphism rs16754 in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, e523-e526.	1.6	26
133	miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. <i>Genes and Development</i> , 2010, 24, 478-490.	5.9	202
134	Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective <i>G-CSF</i> Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 2591-2597.	1.6	62
135	1-(5-Carboxyindol-1-yl)propan-2-one Inhibitors of Human Cytosolic Phospholipase A ₂ with Reduced Lipophilicity: Synthesis, Biological Activity, Metabolic Stability, Solubility, Bioavailability, And Topical in Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5165-5178.	6.4	40
136	1-(5-Carboxyindol-1-yl)propan-2-one Inhibitors of Human Cytosolic Phospholipase A ₂ : Effect of Substituents in Position 3 of the Indole Scaffold on Inhibitory Potency, Metabolic Stability, Solubility, and Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8298-8308.	6.4	31
137	Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. <i>European Journal of Cancer</i> , 2010, 46, 1892-1899.	2.8	20
138	Acute Leukemias in Children with Down Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 19-34.	2.2	35
139	Cardiac Involvement in Churg-Strauss Syndrome. <i>Medicine (United States)</i> , 2009, 88, 236-243.	1.0	206
140	International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2009, 147, 125-128.	2.5	69
141	Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. <i>Blood</i> , 2009, 113, 5951-5960.	1.4	112
142	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , 2009, 114, 2489-2496.	1.4	383
143	Significance of age in acute myeloid leukemia patients younger than 30 years. <i>Cancer</i> , 2008, 112, 562-571.	4.1	91
144	Acute Leukemias in Children with Down Syndrome. <i>Pediatric Clinics of North America</i> , 2008, 55, 53-70.	1.8	49

#	ARTICLE	IF	CITATIONS
145	Toxic Myocarditis due to Oral Ingestion of Hydrofluoric Acid. Heart Lung and Circulation, 2008, 17, 248-250.	0.4	5
146	Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood, 2008, 111, 4322-4328.	1.4	118
147	Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. Blood, 2008, 111, 2899-2903.	1.4	9
148	Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood, 2008, 111, 2991-2998.	1.4	228
149	Activating mutations in human acute megakaryoblastic leukemia. Blood, 2008, 112, 4220-4226.	1.4	141
150	Preanalytical mRNA Stabilization of Whole Bone Marrow Samples. Clinical Chemistry, 2007, 53, 587-593.	3.2	19
151	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood, 2007, 109, 4641-4647.	1.4	126
152	Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood, 2007, 109, 936-943.	1.4	52
153	Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. Blood, 2007, 110, 2027-2033.	1.4	39
154	Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatric Blood and Cancer, 2007, 48, 651-662.	1.5	83
155	Does modulation of P-glycoprotein have clinical relevance in pediatric acute myeloid leukemia?. Blood, 2006, 107, 4975-4977.	1.4	4
156	Clinical implications of FLT3 mutations in pediatric AML. Blood, 2006, 108, 3654-3661.	1.4	355
157	Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood, 2006, 108, 3504-3513.	1.4	70
158	Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group. Journal of Clinical Oncology, 2006, 24, 3686-3692.	1.6	132
159	Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98. Journal of Clinical Oncology, 2006, 24, 4499-4506.	1.6	173
160	Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3339-3344.	7.1	173
161	In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood, 2005, 106, 3532-3537.	1.4	32
162	Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry Part B - Clinical Cytometry, 2005, 63B, 1-9.	1.5	77

#	ARTICLE	IF	CITATIONS
163	Spontaneous complete and sustained remission of a rearrangement CBP (16p13)-positive disseminated congenital myelosarcoma. <i>Annals of Hematology</i> , 2005, 84, 274-275.	1.8	19
164	Concomitant Ewing sarcoma and acute lymphoblastic leukemia in a 5-year-old girl. <i>Pediatric Blood and Cancer</i> , 2005, 45, 846-849.	1.5	7
165	Impact of the Cyclooxygenase System on Doxorubicin-Induced Functional Multidrug Resistance 1 Overexpression and Doxorubicin Sensitivity in Acute Myeloid Leukemic HL-60 Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 346-354.	2.5	48
166	Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2004, 22, 4384-4393.	1.6	230
167	Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 291-296.	2.8	11
168	Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: Almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 393-401.	2.8	70
169	Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. <i>Medical and Pediatric Oncology</i> , 2003, 40, 293-301.	1.0	25
170	Population pharmacokinetics of liposomal daunorubicin in children. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 370-377.	2.4	29
171	Impact of Conventional Chemotherapy on Levels of Antibodies Against Vaccine-Preventable Diseases in Children Treated for Cancer. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 851-857.	1.5	54
172	Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. <i>Blood</i> , 2003, 101, 3868-3871.	1.4	94
173	Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. <i>Blood</i> , 2003, 101, 2001-2007.	1.4	114
174	FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. <i>Blood</i> , 2003, 102, 2387-2394.	1.4	214
175	Minimising the Long-Term Adverse Effects of Childhood Leukaemia Therapy. <i>Drug Safety</i> , 2002, 25, 1057-1077.	3.2	21
176	current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A European view. <i>British Journal of Haematology</i> , 2002, 118, 365-377.	2.5	61
177	Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: a matter of controversies. <i>Blood</i> , 2001, 97, 3671-3672.	1.4	20
178	TUMOUR NECROSIS FACTOR- α EXPRESSION IN IDIOPATHIC DILATED CARDIOMYOPATHY: CORRELATION TO MYOCARDIAL INFLAMMATORY ACTIVITY. <i>Cytokine</i> , 2000, 12, 1261-1266.	3.2	19